HD-OPM Archive
Topics › Lp(a)

Atorvastatin may 'disarm' Lp(a) by blocking oxidation, a theory for HORIZON's failure

Louis Nervegna · Nov 10, 2026 · ♥ 9 reactions · 12 comments · original Facebook post
Lp(a)Statins
AI summary & key facts

Louis proposes that Lp(a)HORIZON failed because aggressive statin treatment (78% on high-intensity statins) may have already neutralized oxidized phospholipids carried by Lp(a). A shared abstract (Sherratt et al., Eur Heart J) found atorvastatin's active metabolite scavenges free radicals and inhibits oxidation of Lp(a) and small dense LDL better than other statins. This is a lab-based hypothesis.

One of the theories why the Lp(a) HORIZON trial failed is because the aggressive treatment of patients with statins and other drugs might have neutralized the deleterious effects of OxPL carried by Lp(a) particles, rendering the lowering of Lp(a) unnecessary.

Lp(a)'s harmful effects may actually stem from the oxidized phospholipids (OxPL) that it carries: facebook.com/share/p/1JEgpfYVSK.

Neutralizing these oxidized phospholipids might cancel the harm of high Lp(a).

Sam Tsimikas has emphasized this in the past, and has recently brought it up again on Twitter: ↪ Tsimikas: Lp(a) risk can be managed with LDL under 65 and tight risk-factor control.

78% of the patients in HORIZON were on high-intensity statins, and most of the rest were at least taking lower doses.

Atorvastatin seems to be particularly effective at neutralizing OxPL.

Colloquially speaking, atorvastatin might "disarm" the Lp(a) particles.

Atorvastatin might make the Lp(a) particles less dangerous by preventing them from carrying the oxidized phospholipids (OxPL) that cause damage to arteries and promote clotting.

cc: Jared Bell

#atorvastatinHD #lpaHD #oxplHD #horizonHD #statinsHD #statinslpaHD

Research cited

Shared from Jared Bell · original post

This specific study (Sherratt et al., published as an abstract in the European Heart Journal) provides a very compelling mechanistic argument for using atorvastatin over other statins if your primary concern is Lp(a) and OxPL-ApoB.

The trial actually shows
The study looked at how different statins interact with the "oxidation" process of cholesterol particles.

Paper · European Heart JournalEuropean Heart Journal articleacademic.oup.com
← newer: Lp(a) makes clots form more easily and resist breakdown via older: Tsimikas: Lp(a) risk can be managed with LDL under 65 and ti →